Developing drugs that can cross the blood-brain barrier: applications to Alzheimer's disease

Development of therapeutics for the central nervous system is one of the most challenging areas in drug development. This is primarily because, in addition to all of the other complications one faces in developing new drugs targeting peripheral sites, one must also negotiate the blood-brain barrier (BBB). There are dozens of strategies to overcome the obstacle of the BBB, but many of these are bound to fail, barring extreme serendipity, because they are based on an inaccurate or incomplete picture of the BBB. This article therefore starts with a brief review of the BBB as it pertains to drug development. It then examines some examples of the delivery of drugs to the central nervous system that are relevant to Alzheimer's disease, placing emphasis on peptides, antibodies, and antisense oligonucleotides.

• Publication year

  2008

• Venue

  BMC Neuroscience

• Publication date

  2008-12-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/1471-2202-9-S3-S2PMID 19090999PMCID 2604887
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ghrelin controls hippocampal spine synapse density and memory performance

  2006cited by this paper
• Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.

  2004cited by this paper
• Transcytosis of macromolecules through the blood-brain barrier: a cell biological perspective and critical appraisal

  2004cited by this paper
• Clearing amyloid through the blood–brain barrier

  2004cited by this paper
• Transport of Cytokines and Neurotrophins across the Blood–Brain Barrier and Their Regulation after Spinal Cord Injury

  2004cited by this paper
• Pharmacological Profiles of Peptide Drug Candidates for the Treatment of Alzheimer's Disease*

  2003cited by this paper
• Is obesity a disease of the blood-brain barrier? Physiological, pathological, and evolutionary considerations.

  2003cited by this paper
• Blood-Spinal Cord and Brain Barriers in Health and Disease : Blood-spinal cord and brain barriers

  2003cited by this paper
• Delivery across the blood-brain barrier of antisense directed against amyloid beta: reversal of learning and memory deficits in mice overexpressing amyloid precursor protein.

  2001cited by this paper
• Physiology of the CSF and Blood-Brain Barriers

  1996cited by this paper

• Unlocking the Gates: Therapeutic Agents for Noninvasive Drug Delivery Across the Blood-Brain Barrier.

  2024cites this paper
• Omnidirectional improvement of mitochondrial health in Alzheimer's disease by multi-targeting engineered activated neutrophil exosomes.

  2024cites this paper
• Ion transporter cascade, reactive astrogliosis and cerebrovascular diseases

  2024influential citation
• A review of natural products and small‐molecule therapeutics acting on central nervous system malignancies: Approaches for drug development, targeting pathways, clinical trials, and challenges

  2024cites this paper
• Rodent Model Preclinical Assessment of PEGylated Block Copolymer Targeting Cognition and Oxidative Stress Insults of Alzheimer’s Disease

  2023cites this paper
• Amyloid fishing: β-Amyloid adsorption using tailor-made coated titania nanoparticles.

  2022cites this paper
• Antibody Delivery into the Brain by Radiosensitizer Nanoparticles for Targeted Glioblastoma Therapy

  2022cites this paper
• Alzheimer’s Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound

  2022cites this paper
• A New Hypothesis for Alzheimer’s Disease: The Lipid Invasion Model

  2022cites this paper
• Dendrimer Architectonics to Treat Cancer and Neurodegenerative Diseases with Implications in Theranostics and Personalized Medicine.

  2021cites this paper
• Central Nervous System Delivery of Antibodies and Their Single-Domain Antibodies and Variable Fragment Derivatives with Focus on Intranasal Nose to Brain Administration

  2021cites this paper
• ROLE OF DRUG DISCOVERY IN CENTRAL NERVOUS SYSTEM DISORDERS: AN OVERVIEW

  2021cites this paper
• Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies

  2020cites this paper
• Neurotheranostics as personalized medicines.

  2019cites this paper
• The “rights” of precision drug development for Alzheimer’s disease

  2019cites this paper
• Effects of Febuxostat on Autistic Behaviors and Computational Investigations of Diffusion and Pharmacokinetics

  2019influential citation
• A lipid-invasion model for Alzheimer’s Disease

  2019cites this paper
• Blood Brain Barrier Crossing for Therapeutic and Diagnostic Agents

  2019cites this paper
• A Reconfigurable In Vitro Model for Studying the Blood–Brain Barrier

  2019cites this paper
• A lipid-leakage model for Alzheimer’s Disease

  2019cites this paper
• Discovery of Neuroregenerative Peptoid from Amphibian Neuropeptide That Inhibits Amyloid-β Toxicity and Crosses Blood-Brain Barrier.

  2018cites this paper
• Genesis of Neuroprotective Peptoid from Aβ30-34 Inhibits Aβ Aggregation and AChE Activity.

  2018cites this paper
• A Systematic Review of Antiamyloidogenic and Metal-Chelating Peptoids: Two Structural Motifs for the Treatment of Alzheimer’s Disease

  2018influential citation
• 2-Hydroxypropyl-β-cyclodextrins and the Blood-Brain Barrier: Considerations for Niemann-Pick Disease Type C1

  2017cites this paper
• Serendipity Based Medicine (SBM): To Infinity and Beyond

  2017cites this paper
• Macrophage exosomes as natural nanocarriers for protein delivery to inflamed brain.

  2017cites this paper
• Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain

  2016cites this paper
• 22. Case Study 1

  2015cites this paper
• Radiolabeled peptides for Alzheimer's diagnostic imaging: mini review.

  2014cites this paper
• Cerebroprotective action of angiotensin peptides in stroke.

  2014cites this paper
• Liposomes bi-functionalized with phosphatidic acid and an ApoE-derived peptide affect Aβ aggregation features and cross the blood-brain-barrier: implications for therapy of Alzheimer disease.

  2014cites this paper
• Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies.

  2014cites this paper
• Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier

  2013cites this paper
• In vivo SELEX for Identification of Brain-penetrating Aptamers

  2013cites this paper
• Devices for cell transplantation into the central nervous system: Design considerations and emerging technologies

  2013cites this paper
• Aβ42-binding peptoids as amyloid aggregation inhibitors and detection ligands.

  2013cites this paper
• Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration.

  2013cites this paper
• Colostrinin: a proline-rich polypeptide complex of potential therapeutic interest.

  2013cites this paper
• Couch Blood-Brain Barrier Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the

  2013cites this paper
• MicroRNAs and multiple sclerosis: from physiopathology toward therapy

  2013cites this paper
• Developing Therapeutic Antibodies for Neurodegenerative Disease

  2013cites this paper
• Role of Biotechnology in Drug Delivery to the Nervous System

  2013cites this paper
• New targets and therapeutic approaches in inherited metabolic disorders

  2013cites this paper
• The SAMP8 mouse: a model to develop therapeutic interventions for Alzheimer's disease.

  2012cites this paper
• Can leptin-derived sequence-modified nanoparticles be suitable tools for brain delivery?

  2012cites this paper
• Interactions of endogenous and exogenous molecules with the human blood-brain barrier

  2012cites this paper
• Qualitative prediction of blood–brain barrier permeability on a large and refined dataset

  2011cites this paper
• Targeted liposomes for drug delivery across the blood-brain barrier

  2011cites this paper
• MR-guided real-time convection-enhanced delivery

  2011cites this paper
• BDNF Plasma Level als Marker für Alzheimer in der VITA- Studie

  2011cites this paper
• Anticorps humains et leurs utilisations diagnostiques et thérapeutiques dans le traitement de troubles neurologiques

  2011cites this paper
• Pseudoexon exclusion by antisense therapy in 6‐pyruvoyl‐tetrahydropterin synthase deficiency

  2011cites this paper
• Simvastatin and other HMG-CoA reductase inhibitors on brain cholesterol levels in Alzheimer's disease.

  2011cites this paper
• Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain.

  2011cites this paper
• In Vivo Methods to Study Uptake of Nanoparticles into the Brain

  2010cites this paper
• Colostral proline-rich polypeptides--immunoregulatory properties and prospects of therapeutic use in Alzheimer's disease.

  2010cites this paper
• Leptin-derived peptide, a targeting ligand for mouse brain-derived endothelial cells via macropinocytosis.

  2010cites this paper
• The synergistic use of computation, chemistry and biology to discover novel peptide-based drugs: the time is right.

  2010cites this paper
• [The blood-brain barrier and drug delivery in the central nervous system].

  2010cites this paper
• Targeting the Blood-brain Barrier with a Non-canonical Iron-mimicry Mechanism

  2010cites this paper
• Tutorial on Drug Development for Central Nervous System

  2010cites this paper
• Intranasal delivery of ESBA105, a TNF-alpha-inhibitory scFv antibody fragment to the brain.

  2009influential citation
• Uptake of apolipoprotein E fragment coupled liposomes by cultured brain microvessel endothelial cells and intact brain capillaries

  2009cites this paper